These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37975050)

  • 1. Von Willebrand Factor as a Biomarker for Liver Disease - An Update.
    Elhence A; Shalimar
    J Clin Exp Hepatol; 2023; 13(6):1047-1060. PubMed ID: 37975050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.
    Ferlitsch M; Reiberger T; Hoke M; Salzl P; Schwengerer B; Ulbrich G; Payer BA; Trauner M; Peck-Radosavljevic M; Ferlitsch A
    Hepatology; 2012 Oct; 56(4):1439-47. PubMed ID: 22532296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
    Mandorfer M; Schwabl P; Paternostro R; Pomej K; Bauer D; Thaler J; Ay C; Quehenberger P; Fritzer-Szekeres M; Peck-Radosavljevic M; Trauner M; Reiberger T; Ferlitsch A;
    Aliment Pharmacol Ther; 2018 Apr; 47(7):980-988. PubMed ID: 29377193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death.
    Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Schwabl P; Stättermayer AF; Pinter M; Eigenbauer E; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1362-1373.e6. PubMed ID: 34256145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis.
    Zou Z; Yan X; Li C; Li X; Ma X; Zhang C; Ju S; Tian J; Qi X
    BMJ Open; 2019 Aug; 9(8):e025656. PubMed ID: 31473610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
    Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
    PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis.
    Wu H; Yan S; Wang G; Cui S; Zhang C; Zhu Q
    Scand J Gastroenterol; 2015; 50(9):1160-9. PubMed ID: 25877661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
    La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
    Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Willebrand Factor Antigen Improves Risk Stratification for Patients with a Diagnosis of Resectable Hepatocellular Carcinoma.
    Pereyra D; Mandorfer M; Santol J; Gregory L; Koeditz C; Ortmayr G; Schuetz C; Rumpf B; Ammon D; Laengle J; Schwarz C; Jonas JP; Pinter M; Lindenlaub F; Tamandl D; Thiels C; Warner S; Smoot R; Truty M; Kendrick M; Nagorney D; Cleary S; Gruenberger T; Reiberger T; Starlinger P
    Ann Surg Oncol; 2024 Jun; ():. PubMed ID: 38896229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.
    Langholm LL; Manon-Jensen T; Karsdal MA; Bendtsen F; Leeming DJ; Møller S
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1040-1048. PubMed ID: 30768435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia.
    Kalambokis GN; Oikonomou A; Christou L; Kolaitis NI; Tsianos EV; Christodoulou D; Baltayiannis G
    J Hepatol; 2016 Nov; 65(5):921-928. PubMed ID: 27297911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.
    Prasanna KS; Goel A; Amirtharaj GJ; Ramachandran A; Balasubramanian KA; Mackie I; Zachariah U; Sajith KG; Elias E; Eapen CE
    Indian J Gastroenterol; 2016 Nov; 35(6):432-440. PubMed ID: 27822882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease.
    Pomej K; Scheiner B; Balcar L; Nussbaumer RJ; Weinzierl J; Paternostro R; Simbrunner B; Bauer D; Pereyra D; Starlinger P; Stättermayer AF; Pinter M; Trauner M; Quehenberger P; Reiberger T; Mandorfer M
    Dig Liver Dis; 2022 Oct; 54(10):1376-1384. PubMed ID: 35871985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von-Willebrand factor as a predictor of three-month mortality in patients with liver cirrhosis compared to MELD score.
    Curakova Ristovska E; Genadieva-Dimitrova M; Caloska-Ivanova V; Misevski J
    Acta Gastroenterol Belg; 2019; 82(4):487-493. PubMed ID: 31950803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C.
    Takaya H; Kawaratani H; Tsuji Y; Nakanishi K; Saikawa S; Sato S; Sawada Y; Kaji K; Okura Y; Shimozato N; Kitade M; Akahane T; Moriya K; Namisaki T; Mitoro A; Matsumoto M; Fukui H; Yoshiji H
    United European Gastroenterol J; 2018 Nov; 6(9):1401-1409. PubMed ID: 30386613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Willebrand factor delays liver repair after acetaminophen-induced acute liver injury in mice.
    Groeneveld D; Cline-Fedewa H; Baker KS; Williams KJ; Roth RA; Mittermeier K; Lisman T; Palumbo JS; Luyendyk JP
    J Hepatol; 2020 Jan; 72(1):146-155. PubMed ID: 31606553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CT-derived liver and spleen volume accurately diagnose clinically significant portal hypertension in patients with hepatocellular carcinoma.
    Romero-Cristóbal M; Clemente-Sánchez A; Ramón E; Téllez L; Canales E; Ortega-Lobete O; Velilla-Aparicio E; Catalina MV; Ibáñez-Samaniego L; Alonso S; Colón A; Matilla AM; Salcedo M; Albillos A; Bañares R; Rincón D
    JHEP Rep; 2023 Mar; 5(3):100645. PubMed ID: 36691569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
    Starlinger P; Ahn JC; Mullan A; Gyoeri GP; Pereyra D; Alva-Ruiz R; Hackl H; Reiberger T; Trauner M; Santol J; Simbrunner B; Mandorfer M; Berlakovich G; Kamath PS; Heimbach J
    Hepatology; 2021 Sep; 74(3):1533-1545. PubMed ID: 33786862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
    Reuken PA; Kussmann A; Kiehntopf M; Budde U; Stallmach A; Claus RA; Bruns T
    Liver Int; 2015 Jan; 35(1):37-45. PubMed ID: 25113276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.